Form D · Biotechnology
Advanced Inhalation Therapies (AIT) Ltd.
Rehovot, L3 · CIK 0001602294
Offering snapshot reported Feb 1, 2017 · SEC filing
- Reported sold
- $10.2M Offering amount: $10.2M
- Investors reported
- 39 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 13, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 1, 2017 | Initial | $10,209,468 | No comparison | 39 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $604K
- Finders' fees
- $0
- Form D file number
- 021-279841
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Ladenburg Thalmann & Co. Inc. | 505 |
Source: Form D, filed Feb 1, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Yossef Av Gay | Director |
| Amir Avniel | Director, Executive |
| Ron Bentsur | Director |
| David Grossman | Director |
| Steven A. Lisi | Director |
| Ari Raved | Director |
| Racheli Vizman | Executive |
| Jerome B. Zeldis | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2 Derech Meir Weisgal
Rehovot, L3, 763205
Rehovot, L3, 763205